

SUPPLEMENTANTARY FIGURE

To the manuscript entitled:

The emerging plasma biomarker Dickkopf-3 (DKK3) and its association with renal and cardiovascular disease in the general population

Arnold Piek¹, Leonie Smit¹, Navin Suthahar¹, Stephan J.L. Bakker², Rudolf A. de Boer¹,
Herman H.W. Silljé¹

¹ Department of Cardiology, University Medical Center Groningen, University of Groningen,
The Netherlands

² Department of Internal Medicine, University Medical Center Groningen, University of
Groningen, The Netherlands

*Corresponding author:

H.H.W. Silljé, PhD


Department of Cardiology, University Medical Center Groningen

University of Groningen

Hanzeplein 1, 9713 GZ Groningen, The Netherlands

P.O. Box 30.001, 9700 RB Groningen, The Netherlands

Phone: +31 50 361 5523, fax: +31 50 3611347, email: h.h.w.sillje@umcg.nl



Supplementary Figure 1. Schematic depiction of the study subject selection procedure.

A total of 85421 subjects aged 28-75 years were invited to participate in this cohort study. A

response was received from a total of 40856 subjects. Of these, 9966 subjects had a morning urinary albumin concentration (UAC) > 10 mg/L and 30890 an UAE < 10 mg/L. Exclusion criteria were insulin usage, current pregnancy or no consent. A random sample was drawn from the subpopulation with an UAC < 10 mg/L. Hereafter, a small group of subjects declined to participate. The final cohort consisted of 8592 subjects, of which 6000 had an UAC > 10 mg/L and 2592 an UAC < 10 mg/L. A total of 172 plasma samples were unavailable for baseline Dickkopf-3 (DKK3) plasma measurement, thus 8420 subjects DKK3 plasma concentrations were measured. At baseline, 1361 subjects had a history of chronic kidney disease (CKD) and 564 had a history of cardiovascular disease (CVD). During follow-up, new-onset CKD was observed in 951 subjects and new-onset CVD in 669 subjects.